Last $0.29 USD
Change Today +0.055 / 23.40%
Volume 106.8K
TNIB On Other Exchanges
As of 3:59 PM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

tni biotech inc (TNIB) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/22/13 - $3.20
52 Week Low
10/15/14 - $0.13
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TNI BIOTECH INC (TNIB)

Related News

No related news articles were found.

tni biotech inc (TNIB) Related Businessweek News

No Related Businessweek News Found

tni biotech inc (TNIB) Details

TNI BioTech, Inc. focuses on the development and commercialization of therapeutic treatments for cancer, HIV/AIDS and autoimmune diseases and immune disorders in the United States. The company develops IRT-101, an active immunotherapy systemic administration of methionine-enkephalin that works by stimulating and/or regulating a patient’s immune system against infectious diseases, autoimmune diseases, immune disorders, and tumor cells. It also develops IRT-103, an adaptive immunotherapy for the treatment of various autoimmune diseases, such as Crohn's disease and multiple sclerosis; HIV/AIDS; and cancer. TNI BioTech, Inc. is headquartered in Orlando, Florida.

12 Employees
Last Reported Date: 03/31/14

tni biotech inc (TNIB) Top Compensated Officers

Chairman, Chief Executive Officer and Founder
Total Annual Compensation: $341.7K
President and Director
Total Annual Compensation: $85.1K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $60.0K
Chief Operating Officer, Secretary and Direct...
Total Annual Compensation: $259.4K
Chief Science Officer
Total Annual Compensation: $60.0K
Compensation as of Fiscal Year 2013.

tni biotech inc (TNIB) Key Developments

TNI BioTech, Inc. has Changed its Name to Immune Therapeutics, Inc

TNI BioTech, Inc. changed its name to Immune Therapeutics, Inc.

TNI BioTech, Inc. Announces First Shipment of Lodonal(R) to the Republic of Panama and the Republic of Malawi

TNI BioTech, Inc. announced it had received payment and will make its first shipments of Lodonal(R) to the Republic of Panama and The Republic of Malawi in conjunction with The Brewer Group, Inc. Lodonal(R) is an active immunotherapy with low dose naltrexone (LDN), an oral medication that works by activating a patient's immune system against HIV/AIDS and tumor cells or by rebalancing the immune system of patients with autoimmune diseases with no toxic side effects. Lodonal(R) competes in the advanced cancer and autoimmune drug market. Global Industry Analysis, Inc. recently released a comprehensive global report on the Autoimmune Disease Therapeutics market, which stated that the global market for Autoimmune Disease Therapeutics is projected to exceed USD 77 billion by the year 2017, driven by the rising incidence of autoimmune complications worldwide. The company believes that Lodonal(R) has demonstrated potential clinical and economic advantages over existing treatments for a number of chronic and acute autoimmune diseases, such as HIV/AIDS, certain cancers, rheumatoid arthritis, multiple sclerosis, Crohn's Disease and inflammatory bowel disease.

TNI BioTech, Inc. Enters into Supplementary Agreement on New Drug Methionine - Enkephalin Cooperation with Hubei Qianjiang Pharmaceutical Co., Ltd

On August 6, 2014, TNI BioTech, Inc. entered into a Supplementary Agreement on New Drug Methionine - Enkephalin Cooperation (the Amendment) with Hubei Qianjiang Pharmaceutical Co., Ltd., amending that certain Venture Cooperation Agreement on New Drug Methionine Enkephalin dated October 18, 2012, as amended by an Addendum to Venture Cooperation and a Supplementary Cooperation Agreement on New Drug Methionine Enkephalin. The Company and Qianjiang Pharmaceutical executed the Amendment to accelerate clinical trials in both the United States and China, and agreed to immediately initiate three month Good Laboratory Practice (GLP) Toxicology Studies (rat and dog) within 30 days of signing the Amendment. The Amendment requires that the GLP Toxicology Studies Trials are conducted in China in accordance with international standards and standards acceptable to the U.S. Food and Drug Administration and that the studies include the following: Exploratory Toxicology (nGLP): Dose range finding studies; Different species and methods of administration; Multiple dosing regimens; Estimate the response vs. dose given. Definitive Toxicology (GLP): Performed in collaboration with Calvert; Laboratories (USA) and MPI/Medicillon (China); General toxicology studies; Different species and methods of administration; Immunogenicity study with NHPs.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TNIB:US $0.29 USD +0.055

TNIB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TNIB.
View Industry Companies

Industry Analysis


Industry Average

Valuation TNIB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TNI BIOTECH INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at